Please use this identifier to cite or link to this item:
Title: PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
Author: Molleví, David G.
Aytés Meneses, Álvaro
Padullés Mosella, Laura
Martínez Iniesta, María
Baixeras, Núria
Salazar Soler, Ramón
Ramos Rubio, Emilio
Figueras Aloy, José, 1950-
Capellá, G. (Gabriel)
Villanueva Garatachea, Alberto
Keywords: Metabolisme
Càncer colorectal
Càncer de fetge
Colorectal cancer
Liver cancer
Issue Date: 28-Oct-2008
Publisher: Cancer Research UK
Abstract: Phosphatase PRL-3 has been involved in different types of cancer, especially in metastases from colorectal carcinoma (CRC). In this study, we explored both isoforms of PRL-3 as a biomarker to predict the recurrence of stage IIIB-C CRC. Overexpression of PRL-3 was investigated in primary human colorectal tumours (n=20) and hepatic metastases (n=36) xenografted in nude mice, samples characterised by absence of human non-tumoral cells, showing a high degree of expression in metastases (P=0.001). In 27 cases of matched normal colonic mucosa/primary tumour/hepatic metastases, PRL-3 overexpression occurs in primary tumours vs normal mucosa (P=0.001) and in hepatic metastases vs primary tumours (P=0.045). Besides, our results in a series of 80 stage IIIB-C CRC primary tumours showed that high levels of PRL-3 were an independent predictor of metastasis (P<0.0001; OR: 9.791) in multivariate analysis of a binary logistic regression and that PRL-3 expression tightly correlates with parameters of bad outcome. Moreover, PRL-3 expression associated with poor outcome in univariate (P<0.0001) and multivariate Cox models (hazard ratio: 3.322, 95%, confidence interval: 1.405-7.852, P=0.006). In conclusion, PRL-3 is a good marker of aggressiveness of locally advanced CRS and a promising predictor of distant metastases. Nevertheless, for prognosis purposes, it is imperative to validate the cutoff value of PRL-3 expression in a larger and consecutive series and adjuvant setting.
Note: Versió postprint del document publicat a:
It is part of: British Journal of Cancer, 2008, vol. 99, num. 10, p. 1718-1725
Related resource:
ISSN: 0007-0920
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
606220.pdf310.09 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.